Robert E. Drolet - Concepedia

Author

Robert E. Drolet

United States Military Academy

Also Known As

R.E. Drolet, Robert Drolet, Robert E Drolet, Robert E. Drolet

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

United States Military Academy University of Pittsburgh Michigan State University Merck & Co., Inc., Rahway, NJ, USA (United States)Institute for Neurodegenerative Disorders

About

Robert E. Drolet is an author at United States Military Academy specializing in medicine, neuroscience, and neurodegeneration.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.6K
2	Social Sciences	3	3	275
3	Health Sciences	1	1	21
4	Natural Sciences	1	1	20
5	Biochemistry	1	1	20

Robert E. Drolet

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
A highly reproducible rotenone model of Parkinson's disease Jason R. Cannon, Vı́ctor Tapias, Hye Mee Na, Neurobiology of Disease Parkinson DiseaseNeurochemical BiomarkersNeurologyNeuroscienceReproducible Rotenone Model	2009	774
Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology Robert E. Drolet, Jason R. Cannon, Laura Montero, Neurobiology of Disease Experimental NeuropathologyChronic Rotenone ExposureNeuroprotectionNeurologyNeuroscience	2009	249
Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells Marija Usenovic, Shahriar Niroomand, Robert E. Drolet, Journal of Neuroscience	2015	248
TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation Sarah Jinn, Robert E. Drolet, Paige E. Cramer, Proceedings of the National Academy of Sciences	2017	236
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity Jack D. Scott, Duane E. DeMong, Thomas J. Greshock, Journal of Medicinal Chemistry Drug TargetPharmacotherapyMedicinal ChemistryBrain Kinase ActivityLrrk2 Inhibitors	2017	140
Mice Lacking α-Synuclein have an Attenuated Loss of Striatal Dopamine Following Prolonged Chronic MPTP Administration Robert E. Drolet, Bahareh Behrouz, Keith J. Lookingland, NeuroToxicology Striatal DopamineNeurodegenerative DiseasesMolecular NeuroscienceMedicineNeuropharmacology	2004	116
Alpha‐Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism Tetyana Duka, Milan Rusnak, Robert E. Drolet, The FASEB Journal Neurodegenerative DiseasesMptp ModelAlzheimer's DiseaseImmunologySubchronic Mptp Exposure	2006	110
LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease Emily M. Rocha, Briana R. De Miranda, Sandra L. Castro, Neurobiology of Disease MitophagyCell DeathSynaptic SignalingSocial SciencesCell Autophagy	2019	98
Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease Sarah Jinn, Cornelis Blauwendraat, Dawn Toolan, Human Molecular Genetics	2019	78
Non‐motor parkinsonian pathology in aging A53T α‐Synuclein mice is associated with progressive synucleinopathy and altered enzymatic function Kaitlin Farrell, Sesha Krishnamachari, Ernesto Villanueva, Journal of Neurochemistry AgingProgressive SynucleinopathySynaptic TransmissionTh HyperactivitySynaptic Signaling	2013	61

Page 1